Prenetics Global Limited
NASDAQ:PREMedical - Diagnostics & Research
+$0.43 today
- Market cap
- $185.61M
- Beta
- 0.24
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$4.18
Volume 1.58M
Average 0.22M
PRE Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Prenetics Global LimitedNASDAQ: PRE
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities remains negative
Q1 FY2026 other current liabilities was $0, compared with $14.52M a year earlier. Over 3 fiscal years it compounded at -3.9% a year.
Context
- Other current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, down 7.1 pp from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 15.5M USD
- Year-over-year change
- +2.9%
- 4-year CAGR
- -9.0%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.5M | +2.9% |
| FY2024 | 2024-12-31 | 15.07M | -2.7% |
| FY2023 | 2023-12-31 | 15.49M | -11.3% |
| FY2022 | 2022-12-31 | 17.47M | -22.8% |
| FY2021 | 2021-12-31 | 22.64M | — |
Other Current Liabilities vs competitors
How PRE compares with its peers on the latest reported figures
- PRE's Mar 2026 other current liabilities of $0 is the lowest of the 11 companies compared; the peer median is $3.93M.
- Its year-over-year change of -100.0% is the lowest of 10, against a peer median of +18.1%.
- Other current liabilities amounts to 0.0% of total assets for PRE, versus a peer median of 2.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ATLNAtlantic International Corp. | Dec 2025 | $101.84M | +817.3% | +556.2% | 89.9% |
| Mar 2026 | $18.34M | +31.0% | +14.2% | 30.6% | |
| Mar 2026 | $10.6M | +58.4% | -24.3% | 8.4% | |
| Mar 2026 | $6.05M | +110.5% | +56.6% | 1.6% | |
| Mar 2026 | $4.37M | — | +5.2% | 2.2% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | $3.49M | +18.1% | -13.3% | 8.6% |
| Mar 2026 | $3.2M | -50.0% | -1.2% | 2.5% | |
| Mar 2026 | $1.69M | -29.4% | +111.0% | 2.3% | |
| Mar 2026 | $1.16M | -31.1% | — | 1.7% | |
| Mar 2026 | $269K | -92.6% | -29.6% | 0.4% | |
| Mar 2026 | $0 | -100.0% | -3.9% | 0.0% | |
| Peer median (excluding PRE) | $3.93M | +18.1% | +5.2% | 2.4% | |
Competitors are the stored peer set for PRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35.29M | 146.66M | 45.71M | 52.25M | 32.13M |
| Short-term Investments | 9.91M | 37.46M | 27.03M | 10.56M | 29.36M |
| Net Receivables | 47.05M | 42.5M | 5.29M | 5.61M | 2.98M |
| Inventory | 6.83M | 4.53M | 3.13M | 6.57M | 7.06M |
| Other Current Assets | 7.31M | 4.58M | 8.31M | 3.55M | 11.86M |
| Total Current Assets | 106.89M | 241.81M | 93.66M | 86.15M | 83.39M |
| Property, Plant & Equipment (Net) | 13.04M | 13.1M | 5.78M | 7.81M | 1.76M |
| Goodwill | 3.98M | 33.8M | 29.17M | 37.36M | 0 |
| Intangible Assets | 23.83M | 14.79M | 13.43M | 11.57M | 44.7M |
| Long-term Investments | 0 | 788.47K | 107.84M | 69.33M | 67M |
| Tax Assets | 79.7K | 243.45K | 28K | 0 | 0 |
| Other Non-current Assets | 693.55K | 7.6M | 4.27M | 1.35M | 6.68M |
| Total Non-current Assets | 41.61M | 70.32M | 160.51M | 127.43M | 120.13M |
| Total Assets | 148.51M | 312.13M | 254.17M | 213.58M | 203.52M |
| Account Payables | 9.98M | 7.29M | 1.67M | 3.67M | 7.73M |
| Short-term Debt | 1.67M | 0 | 0 | 0 | 1.33M |
| Tax Payables | 1.22M | 8.65M | 7.44M | 78K | 0 |
| Deferred Revenue | 9.59M | 5.67M | 6.11M | 6.49M | 3.09M |
| Other Current Liabilities | 22.64M | 17.47M | 15.49M | 15.07M | 15.5M |
| Total Current Liabilities | 58.74M | 57.2M | 39.48M | 36.55M | 27.67M |
| Long-term Debt | 486.4M | 0 | 0 | 0 | 437K |
| Deferred Tax Liabilities | 659.5K | 3.19M | 2.62M | 2.17M | 8K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 4.52M | 1.05M | 499K | 460K |
| Total Non-current Liabilities | 490.66M | 11.47M | 4.53M | 5.68M | 1.34M |
| Total Liabilities | 549.4M | 68.67M | 44.01M | 42.23M | 29.01M |
| Common Stock | 1.49K | 13.7K | 18K | 19K | 25K |
| Retained Earnings | 0 | (408.04M) | (470.77M) | (517.07M) | 0 |
| Accumulated OCI | (400.81M) | (185.69M) | (176.03M) | (169.25M) | 0 |
| Other Stockholders Equity | (24K) | 0 | 0 | 0 | 174.58M |
| Minority Interest | (84.98K) | 6.4M | 3.8M | 957K | (93K) |
| Total Equity | (400.89M) | 243.46M | 210.16M | 171.35M | 174.51M |
| Total Debt | 491.67M | 6.65M | 2.37M | 5.77M | 2.2M |
| Net Debt | 456.38M | (140.01M) | (43.34M) | (46.48M) | (29.93M) |
Prenetics Global Limited
NASDAQ:PRE
Intrinsic Alpha fair value
Locked
Current Price
$10.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.